Respiratory Failure Clinical Trial
Official title:
Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol
This is a compassionate use, proof of concept, phase IIb, prospective, interventional, pilot study in which the investigators will evaluate the effects of compassionate-use treatment with IV tirofiban 25 mcg/kg, associated with acetylsalicylic acid IV, clopidogrel PO and fondaparinux 2.5 mg s/c, in patients affected by severe respiratory failure in Covid-19 associated pneumonia who underwent treatment with continuous positive airway pressure (CPAP).
It is a investigator-initiated, compassionate use, prospective, phase 2b, non randomized,
open-label, proof of concept study in which the investigators will evaluate the effects of
compassionate-use treatment with IV tirofiban, associated with acetylsalicylic acid PO,
clopidogrel PO and fondaparinux 2.5 mg s/c, in patients affected by severe respiratory
failure in Covid-19 associated pneumonia who underwent treatment with continuous positive
airway pressure (CPAP).
Patients will be treated with:
1. 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes)
followed by continuous infusion at a rate of 0,15 microgram/kg/minute for 48 hours.
2. acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at
a dose of 75mg daily for 30 days.
3. a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
4. concurrent fondaparinux 2.5 mg s/c per day for the duration of the in hospital stay.
1) Demographics, body mass index, comorbidities, SOFA score, APACHE II score, Glasgow Coma
Scale will be assessed the day the patient is admitted to the IRCU.
2) Blood gas analysis parameters (PaO2, PaCO2, HCO3-, lactates, SaO2, pH), Alveolar-arterial
gradient, P/F ratio, respiratory rate, arterial blood pressure, heart rate and Chest X ray or
Chest CT scan will be collected at admittance following the standard operating procedures of
the IRCU for COVID-19 patients. The same measurement as detailed in 2) will be repeated 1
hour before and 1, 24, 48 and 168 hours after the loading bolus of tirofiban.
Moreover, at admittance, participating patients will undergo a complete blood count, serum
dosage of: creatinine, blood urea nitrogen (BUN), procalcitonin, c-reactive protein,
Prothrombin Time (PT), Partial Thromboplastin Time (PTT), D-Dimer, fibrinogen, bilirubin,
lactate dehydrogenase (LDH), aspartate transaminase (AST). The same assessment will be
repeated the same morning and 24, 48 and 168 hours after the loading dose of tirofiban.
During hospital stay patients will receive continuous vital sign monitoring including:
electrocardiogram tracing, blood arterial pressure, peripheral oxygen saturation and heart
rate. Neurological status, signs of active bleeding or the occurrence of adverse effects will
be monitored during the whole hospital stay.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03909854 -
Pragmatic Investigation of Volume Targeted Ventilation-1
|
N/A | |
Recruiting |
NCT03662438 -
HOPE (Home-based Oxygen [Portable] and Exercise) for Patients on Long Term Oxygen Therapy (LTOT)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04030208 -
Evaluating Safety and Efficacy of Umbulizer in Patients Requiring Intermittent Positive Pressure Ventilation
|
N/A | |
Recruiting |
NCT04542096 -
Real Time Evaluation of Dynamic Changes of the Lungs During Respiratory Support of VLBW Neonates Using EIT
|
||
Recruiting |
NCT04668313 -
COVID-19 Advanced Respiratory Physiology (CARP) Study
|
||
Recruiting |
NCT05883137 -
High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
|
||
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT03943914 -
Early Non-invasive Ventilation and High-flow Nasal Oxygen Therapy for Preventing Delayed Respiratory Failure in Hypoxemic Blunt Chest Trauma Patients.
|
N/A | |
Active, not recruiting |
NCT03472768 -
The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support
|
||
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Not yet recruiting |
NCT02542423 -
Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure.
|
N/A | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01885442 -
TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT01659268 -
Performance of Baccalaureate Nursing Students in Insertion of Laryngeal Mask: a Trial in Mannequins
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01204281 -
Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
|
Phase 4 | |
Completed |
NCT01249794 -
Non Invasive Ventilation After Cardiac Surgery
|
N/A |